These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 28349676

  • 1. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
    McEwan LM, Wong D, Yaxley J.
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
    [Abstract] [Full Text] [Related]

  • 2. Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
    Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [Abstract] [Full Text] [Related]

  • 3. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L, McBean R, Yaxley J, Wong D.
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
    [Abstract] [Full Text] [Related]

  • 4. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C, McBean R, Parsons R, Wong D.
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
    [Abstract] [Full Text] [Related]

  • 5. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 6. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive].
    Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN.
    Prog Urol; 2017 Aug; 27(8-9):474-481. PubMed ID: 28576423
    [Abstract] [Full Text] [Related]

  • 7. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [Abstract] [Full Text] [Related]

  • 8. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate.
    Qiu S, Dong A, Zhu Y, Zuo C.
    Clin Nucl Med; 2022 Sep 01; 47(9):836-838. PubMed ID: 35439204
    [Abstract] [Full Text] [Related]

  • 9. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E.
    Isr Med Assoc J; 2019 Feb 01; 21(2):100-104. PubMed ID: 30772960
    [Abstract] [Full Text] [Related]

  • 10. Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.
    Bailey J, Piert M.
    Curr Urol Rep; 2017 Sep 09; 18(11):84. PubMed ID: 28889366
    [Abstract] [Full Text] [Related]

  • 11. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
    Kim J, Lee S, Kim D, Kim HJ, Oh KT, Kim SJ, Choi YD, Giesel FL, Kopka K, Hoepping A, Lee M, Yun M.
    Eur J Nucl Med Mol Imaging; 2024 May 09; 51(6):1763-1772. PubMed ID: 38200396
    [Abstract] [Full Text] [Related]

  • 12. The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
    BJU Int; 2016 Oct 09; 118 Suppl 3():49-55. PubMed ID: 27659411
    [Abstract] [Full Text] [Related]

  • 13. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
    Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR.
    Eur J Nucl Med Mol Imaging; 2003 Apr 09; 30(4):607-11. PubMed ID: 12589476
    [Abstract] [Full Text] [Related]

  • 14. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
    Sutherland DEK, Azad AA, Murphy DG, Eapen RS, Kostos L, Hofman MS.
    Semin Nucl Med; 2024 Jan 09; 54(1):4-13. PubMed ID: 37400321
    [Abstract] [Full Text] [Related]

  • 15. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
    Queiroz MA, Viana P, Santos A, Bastos D, Etchebehere E, Cerri G.
    Clin Nucl Med; 2016 Sep 09; 41(9):e417-9. PubMed ID: 27276202
    [Abstract] [Full Text] [Related]

  • 16. Visualization of Intermetastatic Heterogeneity in Mixed Neuroendocrine Carcinoma-Acinar Adenocarcinoma of the Prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
    Cai J, Xu W, Meng T, Pang Y, Chen H.
    Clin Nucl Med; 2023 Aug 01; 48(8):743-745. PubMed ID: 37220226
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
    Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T.
    Anticancer Res; 2017 Mar 01; 37(3):1273-1279. PubMed ID: 28314292
    [Abstract] [Full Text] [Related]

  • 18. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS, Iravani A.
    PET Clin; 2017 Apr 01; 12(2):219-234. PubMed ID: 28267455
    [Abstract] [Full Text] [Related]

  • 19. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
    Reesink DJ, Fransen van de Putte EE, Vegt E, De Jong J, van Werkhoven E, Mertens LS, Bex A, van der Poel HG, van Rhijn BW, Horenblas S, Meijer RP.
    J Urol; 2016 Apr 01; 195(4 Pt 1):907-12. PubMed ID: 26598424
    [Abstract] [Full Text] [Related]

  • 20. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May 01; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.